These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21284792)

  • 1. Waste not, want not: free money, moral hazard and value-based prescribing.
    Minhas R
    Int J Clin Pract; 2011 Mar; 65(3):240-2. PubMed ID: 21284792
    [No Abstract]   [Full Text] [Related]  

  • 2. Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure.
    Meredith PA; Jarvis SC
    Int J Clin Pract; 2011 Aug; 65(8):911; author reply 912. PubMed ID: 21762314
    [No Abstract]   [Full Text] [Related]  

  • 3. Easy money? Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class.
    Pitt B; Julius S
    Int J Clin Pract; 2011 Mar; 65(3):242-4. PubMed ID: 21284791
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
    Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
    Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
    McMurray JJ; Swedberg K
    Eur J Heart Fail; 2010 Feb; 12(2):99-103. PubMed ID: 20083618
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
    Barrios Alonso V; Escobar Cervantes C; Calderón Montero A
    Rev Clin Esp; 2005 Oct; 205(10):499-506. PubMed ID: 16238962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
    MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
    [No Abstract]   [Full Text] [Related]  

  • 9. [Angiotensin receptor blockers in chronic heart failure].
    Umemoto S; Kawahara S; Hashimoto R; Matsuzaki M
    Nihon Rinsho; 2003 Sep; 61(9):1683-9. PubMed ID: 14515740
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate in chronic heart failure: an overlooked risk factor.
    Komajda M
    Eur Heart J; 2015 Mar; 36(11):648-9. PubMed ID: 25416328
    [No Abstract]   [Full Text] [Related]  

  • 12. [Candesartan in heart failure: assessment of reduction in mortality and morbidity].
    Tsutsui H
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():507-12. PubMed ID: 17508585
    [No Abstract]   [Full Text] [Related]  

  • 13. Does slow and steady win the race?
    Howlett JG
    J Am Coll Cardiol; 2012 May; 59(20):1796-8. PubMed ID: 22575318
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
    Winkler G; Jermendy G; Matos L
    Orv Hetil; 2003 Sep; 144(38):1861-7. PubMed ID: 14596024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Despite drug treatment, ever second hypertensive patient with morning blood pressure too high].
    MMW Fortschr Med; 2004 Aug; 146(33-34):52. PubMed ID: 15526635
    [No Abstract]   [Full Text] [Related]  

  • 16. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
    Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
    J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan treatment of hypertension--does VALUE add value?
    Lindholm LH
    Lancet; 2004 Jun; 363(9426):2010-1. PubMed ID: 15207946
    [No Abstract]   [Full Text] [Related]  

  • 18. CHARMed - the effects of candesartan in heart failure.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Mar; 6(3):513-6. PubMed ID: 15794741
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
    Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L
    Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan vs losartan and mortality in patients with heart failure.
    Fruhwald F; Pieske B
    JAMA; 2011 Apr; 305(15):1540-1; author reply 1541-2. PubMed ID: 21505131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.